Related references
Note: Only part of the references are listed.Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
Franz X. Schaub et al.
BLOOD (2009)
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
Philip A. Beer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease
Sophie Lanzkron et al.
ANNALS OF INTERNAL MEDICINE (2008)
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Sai Li et al.
BLOOD (2008)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus
S. J. Leedham et al.
GUT (2008)
Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders
Rui Zhao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Annette H. Schmitt-Graeff et al.
HAEMATOLOGICA (2007)
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
Michael W. N. Deininger et al.
CANCER (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
Polycythemia vera is not initiated by JAK2(V17F) mutation
Roberto H. Nussenzveig et al.
EXPERIMENTAL HEMATOLOGY (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and NIMM patients with clonal hematopoiesis
Ross L. Levine et al.
BLOOD (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
J Jelinek et al.
BLOOD (2005)
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:: lineage specificity and clinical correlates
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma
TM Shattuck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease
R Kralovics et al.
BLOOD (2003)
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan
T Nielsen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
